fda gilead - Search News

News

FDA Approves HIV Shot That’s 99.9% Effective

Barron's on MSN · 1d

FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time.

The Food and Drug Administration approved a twice-yearly shot that prevented HIV infections in 99.9% of the people who received it in large clinical trials. The drug, developed by Gilead Sciences and called Yeztugo,

FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over its $28K annual price.

Daily Post Nigeria · 42m

US govt approves new drug for HIV prevention

The United States Food and Drug Administration, FDA, has approved a new long-acting injectable drug, Lenacapavir, for the prevention of HIV. The drug, to

FDA’s gene therapy turmoil unpacked

And other biotech news brought to you by The Readout.

Fierce Pharma2d

FDA signs off on Gilead's landmark long-acting PrEP med, signaling new era in HIV prevention

With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...

2h

New HIV drug’s global access hangs in the balance

HIV and global health activists say the deployment of Gilead’s twice-a-year HIV prevention shot is the world’s best chance to ...

Pharmalittle: We’re reading about FDA forcing out top gene therapy regulator, Gilead’s HIV challenges and more

And more pharma news updates from Pharmalittle.

2d

Should You Buy Gilead Stock At $110?

Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results